While Teva Pharmaceutical Industries Ltd. expects the Federal Trade Commission to approve its acquisition of Allergan PLC's generic business any day, the parties extended the outside date for the closing from July 26 to Oct. 26. Since the companies have already agreed to divest more than 50 products, the FTC may not require them to sell off additional assets.
In a July 13 filing with the Securities and Exchange Commission, Teva reported that it had entered into a third...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?